**Author details**

Cylia Rochat, Nathalie Bernard-Marissal and Bernard L. Schneider\*

\*Address all correspondence to: bernard.schneider@epfl.ch

Brain Mind Institute, Ecole polytechnique fédérale de Lausanne (EPFL), Lausanne, Switzerland

#### **References**


[7] Saxena S, Roselli F, Singh K, Leptien K, Julien JP, Gros-Louis F, et al. Neuroprotection through excitability and mTOR required in ALS motoneurons to delay disease and extend survival. Neuron. 2013;80(1):80–96.

question, it is critical to further develop animal and cellular models of ALS, based on the genes, which have recently been linked to the disease. By comparing these models, it will be possible to pinpoint common pathogenic pathways, and with the development of more specific

This work was supported by the Swiss National Science Foundation (Grant 310030L\_156460) and by ERANET E-Rare FaSMALS (Grant 31ER30\_160673). NBM is supported by the Neuro‐

biomarkers, apply therapies when and where they are the most likely to succeed.

**Acknowledgements**

182 Update on Amyotrophic Lateral Sclerosis

**Author details**

Switzerland

**References**

muscular Research Association Basel (NeRAB).

Cylia Rochat, Nathalie Bernard-Marissal and Bernard L. Schneider\*

Brain Mind Institute, Ecole polytechnique fédérale de Lausanne (EPFL), Lausanne,

in amyotrophic lateral sclerosis. J Neurol Sci. 1997;147(1):81–8.

[1] Kihira T, Yoshida S, Yoshimasu F, Wakayama I, Yase Y. Involvement of Onuf's nucleus

[2] Kanning KC, Kaplan A, Henderson CE. Motor neuron diversity in development and

[3] Frey D, Schneider C, Xu L, Borg J, Spooren W, Caroni P. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron

[4] Pun S, Santos AF, Saxena S, Xu L, Caroni P. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat Neurosci.

[5] Burke RE, Levine DN, Tsairis P, Zajac FE, 3rd. Physiological types and histochemical profiles in motor units of the cat gastrocnemius. J Physiol. 1973;234(3):723–48.

[6] Cullheim S, Fleshman JW, Glenn LL, Burke RE. Membrane area and dendritic structure in type-identified triceps surae alpha motoneurons. J Comp Neurol. 1987;255(1):68–81.

\*Address all correspondence to: bernard.schneider@epfl.ch

disease. Annu Rev Neurosci. 2010;33:409–40.

diseases. J Neurosci. 2000;20(7):2534–42.

2006;9(3):408–19.


[32] Sharma R, Hicks S, Berna CM, Kennard C, Talbot K, Turner MR. Oculomotor dysfunc‐ tion in amyotrophic lateral sclerosis: a comprehensive review. Arch Neurol. 2011;68(7): 857–61.

[20] Schaefer AM, Sanes JR, Lichtman JW. A compensatory subpopulation of motor neurons in a mouse model of amyotrophic lateral sclerosis. J Comp Neurol. 2005;490(3):209–19.

[21] Rosler KM, Truffert A, Hess CW, Magistris MR. Quantification of upper motor neuron loss in amyotrophic lateral sclerosis. Clin Neurophysiol. 2000;111(12):2208–18.

[22] Stewart HG, Andersen PM, Eisen A, Weber M. Corticomotoneuronal dysfunction in ALS patients with different SOD1 mutations. Clin Neurophysiol. 2006;117(8):1850–61.

[23] Ozdinler PH, Benn S, Yamamoto TH, Guzel M, Brown RH, Jr., Macklis JD. Corticospinal motor neurons and related subcerebral projection neurons undergo early and specific neurodegeneration in hSOD1G(9)(3)A transgenic ALS mice. J Neurosci. 2011;31(11):

[24] Jara JH, Villa SR, Khan NA, Bohn MC, Ozdinler PH. AAV2 mediated retrograde transduction of corticospinal motor neurons reveals initial and selective apical dendrite

[25] Zang DW, Cheema SS. Degeneration of corticospinal and bulbospinal systems in the superoxide dismutase 1(G93A G1H) transgenic mouse model of familial amyotrophic

[26] Urushitani M, Sik A, Sakurai T, Nukina N, Takahashi R, Julien JP. Chromograninmediated secretion of mutant superoxide dismutase proteins linked to amyotrophic

[27] Yasvoina MV, Genc B, Jara JH, Sheets PL, Quinlan KA, Milosevic A, et al. eGFP expression under UCHL1 promoter genetically labels corticospinal motor neurons and a subpopulation of degeneration-resistant spinal motor neurons in an ALS mouse

[28] Genc B, Lagrimas AK, Kuru P, Hess R, Tu MW, Menichella DM, et al. Visualization of sensory neurons and their projections in an upper motor neuron reporter line. PLoS

[29] Gautam M, Jara JH, Sekerkova G, Yasvoina MV, Martina M, Ozdinler PH. Absence of alsin function leads to corticospinal motor neuron vulnerability via novel disease

[30] Jara JH, Genc B, Cox GA, Bohn MC, Roos RP, Macklis JD, et al. Corticospinal motor neurons are susceptible to increased ER stress and display profound degeneration in

[31] Thomsen GM, Gowing G, Latter J, Chen M, Vit JP, Staggenborg K, et al. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex. J Neurosci. 2014;34(47):

the absence of UCHL1 function. Cereb Cortex. 2015;25(11):4259–72.

degeneration in ALS. Neurobiol Dis. 2012;47(2):174–83.

lateral sclerosis. Neurosci Lett. 2002;332(2):99–102.

lateral sclerosis. Nat Neurosci. 2006;9(1):108–18.

model. J Neurosci. 2013;33(18):7890–904.

mechanisms. Hum Mol Genet. 2016.

One. 2015;10(7):e0132815.

15587–600.

4166–77.

184 Update on Amyotrophic Lateral Sclerosis


SOD1 in neurons and astrocytes. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(3):163–84.


activity and contributes to motor neuron vulnerability in ALS. Acta Neuropathol. 2016;131(3):427–51.

[57] Le Masson G, Przedborski S, Abbott LF. A computational model of motor neuron degeneration. Neuron. 2014;83(4):975–88.

SOD1 in neurons and astrocytes. Amyotroph Lateral Scler Other Motor Neuron Disord.

[45] Forsberg K, Andersen PM, Marklund SL, Brannstrom T. Glial nuclear aggregates of superoxide dismutase-1 are regularly present in patients with amyotrophic lateral

[46] Lobsiger CS, Boillee S, Cleveland DW. Toxicity from different SOD1 mutants dysre‐ gulates the complement system and the neuronal regenerative response in ALS motor

[47] Gros-Louis F, Soucy G, Lariviere R, Julien JP. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem. 2010;113(5):1188–99.

[48] Bernard-Marissal N, Moumen A, Sunyach C, Pellegrino C, Dudley K, Henderson CE, et al. Reduced calreticulin levels link endoplasmic reticulum stress and Fas-triggered

cell death in motoneurons vulnerable to ALS. J Neurosci. 2012;32(14):4901–12.

[49] Bernard-Marissal N, Sunyach C, Marissal T, Raoul C, Pettmann B. Calreticulin levels determine onset of early muscle denervation by fast motoneurons of ALS model mice.

[50] Filezac de L'Etang A, Maharjan N, Cordeiro Brana M, Ruegsegger C, Rehmann R, Goswami A, et al. Marinesco-Sjogren syndrome protein SIL1 regulates motor neuron

[51] Dobrowolny G, Aucello M, Molinaro M, Musaro A. Local expression of mIgf-1 modulates ubiquitin, caspase and CDK5 expression in skeletal muscle of an ALS mouse

[52] Millers EK, Masci PP, Lavin MF, de Jersey J, Guddat LW. Crystallization and prelimi‐ nary X-ray analysis of a Kunitz-type inhibitor, textilinin-1 from Pseudonaja textilis textilis. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006;62(Pt 7):642–5.

[53] Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic

[54] He X, Zhang L, Yao X, Hu J, Yu L, Jia H, et al. Association studies of MMP-9 in Parkinson's disease and amyotrophic lateral sclerosis. PLoS One. 2013;8(9):e73777.

[55] Jokic D, Boudon C, Pognon G, Bonin M, Schenk KJ, Gross M, et al. Structural and binding features of cofacial bis-porphyrins with calixarene spacers: pac-man porphyr‐

[56] Ruegsegger C, Maharjan N, Goswami A, Filezac de L'Etang A, Weis J, Troost D, et al. Aberrant association of misfolded SOD1 with Na(+)/K(+)ATPase-alpha3 impairs its

subtype-selective ER stress in ALS. Nat Neurosci. 2015;18(2):227–38.

sclerosis. Acta Neuropathol. 2011;121(5):623–34.

neurons. Proc Natl Acad Sci U S A. 2007;104(18):7319–26.

2000;1(3):163–84.

186 Update on Amyotrophic Lateral Sclerosis

Neurobiol Dis. 2015;73:130–6.

model. Neurol Res. 2008;30(2):131–6.

chondrocytes. Cell. 1998;93(3):411–22.

ins that can chew. Chemistry. 2005;11(14):4199–209.


glia in mutant SOD1-mediated ALS. Proc Natl Acad Sci U S A. 2015;112(50):E6993– 7002.


[82] Aebischer J, Bernard-Marissal N, Pettmann B, Raoul C. Death receptors in the selective degeneration of motoneurons in amyotrophic lateral sclerosis. J Neurodegener Dis. 2013;2013:746845.

glia in mutant SOD1-mediated ALS. Proc Natl Acad Sci U S A. 2015;112(50):E6993–

[70] Heiman M, Schaefer A, Gong S, Peterson JD, Day M, Ramsey KE, et al. A translational profiling approach for the molecular characterization of CNS cell types. Cell.

[71] Nave KA. Myelination and the trophic support of long axons. Nat Rev Neurosci.

[72] Philips T, Bento-Abreu A, Nonneman A, Haeck W, Staats K, Geelen V, et al. Oligoden‐ drocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis. Brain.

[73] Lee Y, Morrison BM, Li Y, Lengacher S, Farah MH, Hoffman PN, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature.

[74] Ferraiuolo L, Higginbottom A, Heath PR, Barber S, Greenald D, Kirby J, et al. Dysre‐ gulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related

[75] Meyer K, Ferraiuolo L, Miranda CJ, Likhite S, McElroy S, Renusch S, et al. Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. Proc Natl Acad Sci U S A.

[76] Haidet-Phillips AM, Hester ME, Miranda CJ, Meyer K, Braun L, Frakes A, et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat

[77] King AE, Woodhouse A, Kirkcaldie MT, Vickers JC. Excitotoxicity in ALS: overstimu‐

[78] Fray AE, Ince PG, Banner SJ, Milton ID, Usher PA, Cookson MR, et al. The expression of the glial glutamate transporter protein EAAT2 in motor neuron disease: an immu‐

[79] Rothstein JD. Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis.

[80] Sasaki S, Komori T, Iwata M. Excitatory amino acid transporter 1 and 2 immunoreac‐ tivity in the spinal cord in amyotrophic lateral sclerosis. Acta Neuropathol. 2000;100(2):

[81] Jaiswal MK. Selective vulnerability of motoneuron and perturbed mitochondrial calcium homeostasis in amyotrophic lateral sclerosis: implications for motoneurons

amyotrophic lateral sclerosis. Brain. 2011;134(Pt 9):2627–41.

lation, or overreaction? Exp Neurol. 2016;275 Pt 1:162–71.

nohistochemical study. Eur J Neurosci. 1998;10(8):2481–9.

specific calcium dysregulation. Mol Cell Ther. 2014;2:26.

7002.

188 Update on Amyotrophic Lateral Sclerosis

2008;135(4):738–48.

2010;11(4):275–83.

2013;136(Pt 2):471–82.

2012;487(7408):443–8.

2014;111(2):829–32.

Biotechnol. 2011;29(9):824–8.

Clin Neurosci. 1995;3(6):348–59.

138–44.


[106] Simonen M, Pedersen V, Weinmann O, Schnell L, Buss A, Ledermann B, et al. Systemic deletion of the myelin-associated outgrowth inhibitor Nogo-A improves regenerative and plastic responses after spinal cord injury. Neuron. 2003;38(2):201–11.

[94] Balice-Gordon RJ. Dynamic roles at the neuromuscular junction. Schwann cells. Curr

[95] Pasterkamp RJ, Giger RJ. Semaphorin function in neural plasticity and disease. Curr

[96] Duchen LW. Changes in motor innervation and cholinesterase localization induced by botulinum toxin in skeletal muscle of the mouse: differences between fast and slow

[97] De Winter F, Vo T, Stam FJ, Wisman LA, Bar PR, Niclou SP, et al. The expression of the chemorepellent Semaphorin 3A is selectively induced in terminal Schwann cells of a subset of neuromuscular synapses that display limited anatomical plasticity and enhanced vulnerability in motor neuron disease. Mol Cell Neurosci. 2006;32(1–2):102–

[98] Venkova K, Christov A, Kamaluddin Z, Kobalka P, Siddiqui S, Hensley K. Semaphorin 3A signaling through neuropilin-1 is an early trigger for distal axonopathy in the SOD1G93A mouse model of amyotrophic lateral sclerosis. J Neuropathol Exp Neurol.

[99] Korner S, Boselt S, Wichmann K, Thau-Habermann N, Zapf A, Knippenberg S, et al. The axon guidance protein semaphorin 3A is increased in the motor cortex of patients

[100] Loeffler JP, Picchiarelli G, Dupuis L, Gonzalez De Aguilar JL. The role of skeletal muscle

[101] Towne C, Raoul C, Schneider BL, Aebischer P. Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease pro‐

[102] Miller TM, Kim SH, Yamanaka K, Hester M, Umapathi P, Arnson H, et al. Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2006;103(51):19546–51.

[103] Jokic N, Gonzalez de Aguilar JL, Pradat PF, Dupuis L, Echaniz-Laguna A, Muller A, et al. Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity.

[104] Bruneteau G, Bauche S, Gonzalez de Aguilar JL, Brochier G, Mandjee N, Tanguy ML, et al. Endplate denervation correlates with Nogo-A muscle expression in amyotrophic

[105] Jokic N, Gonzalez de Aguilar JL, Dimou L, Lin S, Fergani A, Ruegg MA, et al. The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral

lateral sclerosis patients. Ann Clin Transl Neurol. 2015;2(4):362–72.

with amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2016.

in amyotrophic lateral sclerosis. Brain Pathol. 2016.

gression in fALS mice. Mol Ther. 2008;16(6):1018–25.

sclerosis model. EMBO Rep. 2006;7(11):1162–7.

Ann Neurol. 2005;57(4):553–6.

muscles. J Neurol Neurosurg Psychiatry. 1970;33(1):40–54.

Biol. 1996;6(9):1054–6.

190 Update on Amyotrophic Lateral Sclerosis

17.

2014;73(7):702–13.

Opin Neurobiol. 2009;19(3):263–74.


[130] Wang H, Yang B, Qiu L, Yang C, Kramer J, Su Q, et al. Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. Hum Mol Genet. 2014;23(3):668–81.

[118] Wang L, Popko B, Tixier E, Roos RP. Guanabenz, which enhances the unfolded protein response, ameliorates mutant SOD1-induced amyotrophic lateral sclerosis. Neurobiol

[119] Kayatekin C, Zitzewitz JA, Matthews CR. Zinc binding modulates the entire folding free energy surface of human Cu,Zn superoxide dismutase. J Mol Biol. 2008;384(2):540–

[120] Trumbull KA, Beckman JS. A role for copper in the toxicity of zinc-deficient superoxide dismutase to motor neurons in amyotrophic lateral sclerosis. Antioxid Redox Signal.

[121] McAllum EJ, Lim NK, Hickey JL, Paterson BM, Donnelly PS, Li QX, et al. Therapeutic effects of CuII(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis.

[122] Roberts BR, Lim NK, McAllum EJ, Donnelly PS, Hare DJ, Doble PA, et al. Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis.

[123] Williams JR, Trias E, Beilby PR, Lopez NI, Labut EM, Bradford CS, et al. Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SOD mice co-

[124] Liu HN, Tjostheim S, Dasilva K, Taylor D, Zhao B, Rakhit R, et al. Targeting of mono‐ mer/misfolded SOD1 as a therapeutic strategy for amyotrophic lateral sclerosis. J

[125] Patel P, Kriz J, Gravel M, Soucy G, Bareil C, Gravel C, et al. Adeno-associated virusmediated delivery of a recombinant single-chain antibody against misfolded superox‐ ide dismutase for treatment of amyotrophic lateral sclerosis. Mol Ther. 2014;22(3):498–

[126] Turner BJ, Talbot K. Transgenics, toxicity and therapeutics in rodent models of mutant

[127] Foust KD, Salazar DL, Likhite S, Ferraiuolo L, Ditsworth D, Ilieva H, et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends

[128] Ralph GS, Radcliffe PA, Day DM, Carthy JM, Leroux MA, Lee DC, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in

[129] Raoul C, Abbas-Terki T, Bensadoun JC, Guillot S, Haase G, Szulc J, et al. Lentiviralmediated silencing of SOD1 through RNA interference retards disease onset and

SOD1-mediated familial ALS. Prog Neurobiol. 2008;85(1):94–134.

survival in models of inherited ALS. Mol Ther. 2013;21(12):2148–59.

progression in a mouse model of ALS. Nat Med. 2005;11(4):423–8.

an ALS model. Nat Med. 2005;11(4):429–33.

expressing the Copper-Chaperone-for-SOD. Neurobiol Dis. 2016;89:1–9.

Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(7–8):586–90.

Dis. 2014;71:317–24.

192 Update on Amyotrophic Lateral Sclerosis

2009;11(7):1627–39.

J Neurosci. 2014;34(23):8021–31.

Neurosci. 2012;32(26):8791–9.

55.

510.

